Daily Stock Analysis, BTX, BioTime Inc, priceseries

BioTime Inc. Daily Stock Analysis
Stock Information
Open
1.16
Close
1.13
High
1.20
Low
1.11
Previous Close
1.19
Daily Price Gain
-0.06
YTD High
1.73
YTD High Date
Mar 15, 2019
YTD Low
0.85
YTD Low Date
Jan 28, 2019
YTD Price Change
0.09
YTD Gain
8.65%
52 Week High
2.81
52 Week High Date
Sep 5, 2018
52 Week Low
0.66
52 Week Low Date
Dec 21, 2018
52 Week Price Change
-1.20
52 Week Gain
-51.50%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 22. 2018
2.48
Sep 5. 2018
2.63
9 Trading Days
6.10%
Link
LONG
Mar 7. 2019
1.28
Mar 15. 2019
1.35
6 Trading Days
5.66%
Link
Company Information
Stock Symbol
BTX
Exchange
NYSE MKT
Company URL
http://www.biotimeinc.com
Company Phone
5105213390
CEO
Michael D. West
Headquarters
California
Business Address
1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA, CA 94501
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000876343
About

BioTime, Inc. engages in biotechnology business. It focuses on research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.

Description

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. Its product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor (BDNF) directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. The company also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer. In addition, it offers liquid biopsy tests for diagnosis of cancer; bone grafting products to treat orthopedic disorders; and mobile health software products. Further, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants; and GeneAnalytics, a novel gene set analysis tool. Additionally, the company develops and markets Hextend, a blood plasma volume expander used for the treatment of hypovolemia. BioTime, Inc. was founded in 1990 and is based in Alameda, California.